Gosset Ownership
Private
Employees
~4
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
MDI Therapeutics General Information
MDI Therapeutics has initiated a Phase 1 clinical trial of its lead candidate, MDI‑2517, an orally active small molecule PAI‑1 inhibitor. The study aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Preclinical data show efficacy in multiple models of fibrotic disease. Additional pipeline assets are at the preclinical stage targeting related indications such as venous thrombosis.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Novi, Michigan
United States
United States
Drug Pipeline
MDI-2517
Phase 1Key Partnerships
MDI Therapeutics Funding
No funding data available
To view MDI Therapeutics's complete valuation and funding history, request access »